VIVUS, Inc. (NASDAQ:VVUS) CFO Mark K. Oki purchased 10,000 shares of the business’s stock in a transaction on Tuesday, November 6th. The stock was purchased at an average cost of $4.07 per share, for a total transaction of $40,700.00. Following the acquisition, the chief financial officer now owns 10,000 shares in the company, valued at $40,700. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of VIVUS stock opened at $3.65 on Friday. VIVUS, Inc. has a 12-month low of $3.30 and a 12-month high of $9.90.
VIVUS (NASDAQ:VVUS) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.24. The firm had revenue of $18.09 million during the quarter. Equities analysts expect that VIVUS, Inc. will post -3.59 EPS for the current year.
A number of brokerages have issued reports on VVUS. Zacks Investment Research raised shares of VIVUS from a “sell” rating to a “hold” rating in a report on Thursday, September 13th. ValuEngine raised shares of VIVUS from a “hold” rating to a “buy” rating in a report on Thursday, November 1st.
An institutional investor recently raised its position in VIVUS stock. Renaissance Technologies LLC boosted its position in VIVUS, Inc. (NASDAQ:VVUS) by 5.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,273,800 shares of the biopharmaceutical company’s stock after acquiring an additional 423,100 shares during the period. Renaissance Technologies LLC owned 7.79% of VIVUS worth $5,833,000 at the end of the most recent reporting period.
COPYRIGHT VIOLATION WARNING: “VIVUS, Inc. (VVUS) CFO Purchases $40,700.00 in Stock” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/11/10/vivus-inc-vvus-cfo-purchases-40700-00-in-stock.html.
VIVUS Company Profile
VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Read More: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.